We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients with HER2-expressing Solid Tumors
News

MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients with HER2-expressing Solid Tumors

MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients with HER2-expressing Solid Tumors
News

MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients with HER2-expressing Solid Tumors

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients with HER2-expressing Solid Tumors"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, has announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

MGAH22 is an Fc-optimized monoclonal antibody developed by MacroGenics which has been shown, in pre-clinical studies, to reduce tumor growth significantly in a broad panel of HER2-expressing tumors.

"We are excited to have begun clinical testing of MGAH22, a next generation antibody that may have wide application in cancer treatment," stated Dr. Scott Koenig, President and CEO of MacroGenics. "MGAH22 is the first Fc-engineered antibody therapeutic from our oncology pipeline to enter clinical development and represents a major milestone for MacroGenics. Our pre-clinical studies suggest that MGAH22 may provide significant differentiation from the other HER2-targeted immunotherapeutics, including the ability to treat tumors with relatively low levels of HER2 expression."

This open-label, multi-dose, single-arm, multi-center Phase I, dose-escalation study is being conducted to define the toxicity profile, maximum tolerated dose, pharmacokinetics, immunogenicity, and potential antitumor activity of MGAH22 in patients with refractory HER2-positive breast cancer and patients with other carcinomas that overexpress HER2 for whom no standard therapy is available. Additional information on the clinical trial can be found at: http://www.clinicaltrials.gov/ct2/show/NCT01148849.

Advertisement